IP Library Granted Patent US 7,928,061
Granted Patent B2
US 7,928,061 · App. 11/929,120 · Granted Apr 19, 2011

Methods of using VEGF-D polypeptides

Assignee: Vegenics Pty Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,928,061
App. No.
11/929,120
Granted
Apr 19, 2011
Kind
B2
Abstract

Disclosed herein are various uses for VEGF-D polypeptides. Exemplary uses include methods of stimulating endothelial cell proliferation, methods of stimulating vascular permeability, methods of stimulating angiogenesis and methods of activating VEGFR-2 and VEGFR-3 using VEGF-D polypeptides.

Claims (15)

1. A method of stimulating endothelial cell proliferation comprising contacting endothelial cells with an isolated polypeptide that stimulates endothelial cell proliferation, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N- and C-terminal to residues 92-205.

2. The method of claim 1 , wherein the polypeptide comprises at least amino acids 101-196 of SEQ ID NO: 5.

3. The method of claim 2 , wherein the polypeptide lacks amino acids of SEQ ID NO: 5 that are N- and C- terminal to residues 93-201.

4. A method of stimulating vascular permeability comprising contacting endothelial cells with an isolated polypeptide that stimulates vascular permeability, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N- and C-terminal to residues 92-205.

5. The method of claim 4 , wherein the polypeptide comprises at least amino acids 101-196 of SEQ ID NO: 5.

6. The method of claim 5 , wherein the polypeptide lacks amino acids of SEQ ID NO: 5 that are N- and C- terminal to residues 93-201.

7. A method of stimulating angiogenesis comprising administering to a mammalian subject a composition comprising an isolated polypeptide that has at least one activity selected from the group consisting of stimulation of endothelial cell proliferation, stimulation of vascular permeability, binding to the extracellular domain of VEGFR-2 and binding to the extracellular domain of VEGFR-3, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N- and C-terminal to residues 92-205.

8. The method of claim 7 , wherein the polypeptide comprises at least amino acids 101-196 of SEQ ID NO: 5.

9. The method of claim 8 , wherein the polypeptide lacks amino acids of SEQ ID NO: 5 that are N- and C- terminal to residues 93-201.

10. A method of activating VEGF receptor-2 (VEGFR-2) comprising contacting cells bearing said receptor with an amount of an isolated polypeptide that binds to the extracellular domain of VEGFR-2, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N- and C-terminal to residues 92-205; and wherein the cells are contacted with the polypeptide in an amount effective to activate VEGFR-2.

11. The method of claim 10 , wherein the polypeptide comprises at least amino acids 101-196 of SEQ ID NO: 5.

12. The method of claim 11 , wherein the polypeptide lacks amino acids of SEQ ID NO: 5 that are N- and C- terminal to residues 93-201.

13. A method of activating VEGF receptor-3 (VEGFR-3) comprising contacting cells bearing said receptor with an amount of an isolated polypeptide that binds to the extracellular domain of VEGFR-3, wherein the polypeptide comprises a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N- and C-terminal to residues 92-205; and wherein the cells are contacted with the polypeptide in an amount effective to activate VEGFR-3.

14. The method of claim 13 , wherein the polypeptide comprises at least amino acids 101-196 of SEQ ID NO: 5.

15. The method of claim 14 , wherein the polypeptide lacks amino acids of SEQ ID NO: 5 that are N- and C- terminal to residues 93-201.

Assignments (1)
CHANGE OF NAME Recorded Mar 14, 2011
From: VEGENICS LIMITED
To: VEGENICS PTY LTD
Reel/Frame 025949/0946 →
Priority Claims (4)
AU PO 1825 · Aug 23, 1996 · national
AU PO 3554 · Nov 11, 1996 · national
AU PO 4954 · Feb 5, 1997 · national
AU PO 7435 · Jun 19, 1997 · national
Continuity (8)
Continuation 10161694 · Jun 5, 2002
Division 09296275 · Apr 22, 1999
Division 08915795 · Aug 21, 1997
Provisional Application 60023751 · Aug 23, 1996
Provisional Application 60031097 · Nov 14, 1996
Provisional Application 60038814 · Feb 10, 1997
Provisional Application 60051426 · Jul 1, 1997
Related Publication 20080070831A1 · Mar 20, 2008